Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
McKesson
Baxter
Moodys
Merck

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 9,931,330

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,931,330
Title:Methods and devices for the treatment of ocular diseases in human subjects
Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
Inventor(s): Zarnitsyn; Vladimir (Atlanta, GA), Patel; Samirkumar (Atlanta, GA), White; Daniel (Suwanee, GA), Noronha; Glenn (Atlanta, GA), Burke; Brian (Cary, NC)
Assignee: CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA)
Application Number:15/673,073
Patent Claims:see list of patent claims

Details for Patent 9,931,330

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA) 2032-11-08 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA) 2032-11-08 RX Orphan search
Glaxosmithkline Llc BENLYSTA belimumab INJECTABLE;INJECTION 761043 001 2017-07-20   Start Trial CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA) 2032-11-08 RX search
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2017-05-26   Start Trial CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA) 2032-11-08 RX search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA) 2032-11-08 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 002 2011-03-09   Start Trial CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA) 2032-11-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,931,330

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Merck
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.